What is Cocrystal Pharma?
Cocrystal Pharma operates at the intersection of advanced biotechnology and medicinal chemistry, specializing in the discovery and development of novel antiviral therapies. The company utilizes a sophisticated structure-based drug design approach to identify and optimize compounds targeting high-priority viral threats, including hepatitis C, influenza, and various coronavirus strains. By focusing on the molecular architecture of viral proteins, Cocrystal Pharma creates highly specific inhibitors designed to disrupt viral replication cycles.
The company's market position is defined by its commitment to addressing unmet medical needs in the infectious disease space. Through strategic alliances and internal research programs, Cocrystal Pharma maintains a robust portfolio of therapeutic assets. Its operational model emphasizes scientific rigor and the application of cutting-edge computational tools to shorten the timeline from target identification to clinical candidate selection, positioning the firm as a key player in the global effort to combat respiratory and chronic viral diseases.
How much funding has Cocrystal Pharma raised?
Cocrystal Pharma has raised a total of $5M across 1 funding round:
Stock/Share Issuance
$5M
Stock/Share Issuance (2026): $5M with participation from OPKO Health
Key Investors in Cocrystal Pharma
OPKO Health
OPKO Health is a diversified healthcare company focused on the discovery, development, and commercialization of medicines and diagnostic testing services, operating extensively in the pharmaceutical and diagnostics sectors.
What's next for Cocrystal Pharma?
Looking ahead, the strategic deployment of the $5M will likely focus on scaling the company's lead programs and expanding its research capabilities. As Cocrystal Pharma transitions into more advanced stages of development, the focus will shift toward optimizing clinical trial designs and securing regulatory milestones. The company is expected to leverage its existing partnerships to facilitate the transition of its antiviral candidates from the laboratory to human clinical trials, thereby validating its structure-based technology in real-world settings.
Furthermore, the firm is poised to explore additional therapeutic targets, potentially broadening its reach into emerging viral threats. By maintaining a disciplined approach to capital allocation and scientific innovation, Cocrystal Pharma is set to enhance its competitive standing within the biotechnology sector, ultimately aiming to deliver transformative treatments that address the evolving challenges of global viral health.
